CYSTIC FIBROSIS: A BREAKTHROUGH IN 21ST-CENTURY THERAPY

Author:

Simonova Olga I.1ORCID,Gorinova Yulia V.2ORCID,Chernevich Vera P.3

Affiliation:

1. National Medical Research Center for Children Health; I.M. Sechenov First Moscow State Medical University; Morozov Children′s Clinical Hospital

2. National Medical Research Center for Children Health

3. National Medical Research Center for Children Health; Morozov Children′s Clinical Hospital

Abstract

The review presents new data on the latest advances in the treatment of cystic fibrosis, a rare genetic disease. The methods used were literature search in the Scopus, Web of Science, and EMBASE databases. The importance of a number of drugs prescribed for anti-inflammatory purposes (ibuprofen, azithromycin) is discussed, data from multicenter studies of new drugs are presented. The role of mucolytic agents and the need to develop new antibacterial compounds are shown. Particular attention in the review is given to the development of new targeted therapies for cystic fibrosis. The data of studies of ivacaftor, lumacactor, tezacactor in this category of patients are presented, as well as a spectrum of mutations of the cystic fibrosis gene in which these molecules can be prescribed. The experience of the use of correctors in adult patients with cystic fibrosis in the Russian Federation is described, the effectiveness and safety of the long-term use of these drugs are described.

Publisher

National Medical Research Center for Childrens Health

Reference41 articles.

1. Spielberg D.R., Clancy J.P. Cystic fibrosis and its management through established and emerging therapies. Annu. Rev. Genomics Hum. Genet. 2016; 17: 155-75. DOI: http://doi.org/10.1146/annurev-genom-090314-050024

2. Clinical and Functional Translation of CFTR. Available at: http://www.cftr2.org

3. Gorinova Yu.V., Simonova O.I., Lazareva A.V., Chernevich V.P., Smirnov I.E. Experience of the sustainable use of inhalations of tobramycin solution in chronic Pseudomonas aeruginosa infection in children with cystic fibrosis. Rossiyskiy pediatricheskiy zhurnal. 2015; 18(3): 50-3. (in Russian)

4. Kapranov N.I., Perederko L.V., Kashirskaya N.Yu., Pukhal’skiy A.L., Tolstova V.D., Shmarina G.V. Systemic and inhaled corticosteroids in the complex treatment of bronchopulmonary lesions in children. Pediatriya. Zhurnal im. G.N. Speranskogo. 2009; 87(1): 60-8. (in Russian)

5. De Benedictis F.M., Bush A. Corticosteroids in respiratory diseases in children. Am. J. Respir. Crit. Care Med. 2012; 185(1): 12-23. DOI: http://doi.org/10.1164/rccm.201107-1174CI

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Targeted Therapy for Cystic Fibrosis in Children;Innovative Medicine of Kuban;2023-11-17

2. Genotype-phenotype correlation in siblings with cystic fibrosis;Russian Pediatric Journal;2023-06-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3